-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in Q BioMed Inc. (OTCMKTS:QBIO) Grows By 50.0%
Short Interest in Q BioMed Inc. (OTCMKTS:QBIO) Grows By 50.0%
Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 45,900 shares, an increase of 50.0% from the August 15th total of 30,600 shares. Based on an average daily trading volume, of 1,913,000 shares, the days-to-cover ratio is currently 0.0 days.
Q BioMed Stock Performance
QBIO remained flat at $0.02 during trading on Friday. 69,167 shares of the company's stock traded hands, compared to its average volume of 396,902. Q BioMed has a 12 month low of $0.02 and a 12 month high of $0.76. The stock's 50-day moving average is $0.05 and its 200 day moving average is $0.13. The stock has a market capitalization of $1.41 million, a price-to-earnings ratio of -0.08 and a beta of 2.39.
Get Q BioMed alerts:Q BioMed (OTCMKTS:QBIO – Get Rating) last announced its earnings results on Thursday, July 28th. The company reported ($0.06) earnings per share for the quarter. The firm had revenue of $0.17 million for the quarter.
Q BioMed Company Profile
(Get Rating)Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.
See Also
- Get a free copy of the StockNews.com research report on Q BioMed (QBIO)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 45,900 shares, an increase of 50.0% from the August 15th total of 30,600 shares. Based on an average daily trading volume, of 1,913,000 shares, the days-to-cover ratio is currently 0.0 days.
Q BioMed Inc.(場外交易代碼:QBIO-GET Rating)8月份空頭股數銷量大幅增長。截至8月31日,空頭股數共有4.59萬股,比8月15日的3.06萬股增加了50.0%。基於日均成交量1,913,000股,目前天數與回補比率為0.0天。
Q BioMed Stock Performance
Q BioMed股票表現
QBIO remained flat at $0.02 during trading on Friday. 69,167 shares of the company's stock traded hands, compared to its average volume of 396,902. Q BioMed has a 12 month low of $0.02 and a 12 month high of $0.76. The stock's 50-day moving average is $0.05 and its 200 day moving average is $0.13. The stock has a market capitalization of $1.41 million, a price-to-earnings ratio of -0.08 and a beta of 2.39.
在週五的交易中,QBIO持平於0.02美元。該公司股票成交量為69,167股,而其平均成交量為396,902股。Q BioMed的12個月低點為0.02美元,12個月高位為0.76美元。該股的50日移動均線切入位在0.05美元,200日移動均線切入位在0.13美元。該股市值為141萬美元,市盈率為-0.08倍,貝塔係數為2.39。
Q BioMed (OTCMKTS:QBIO – Get Rating) last announced its earnings results on Thursday, July 28th. The company reported ($0.06) earnings per share for the quarter. The firm had revenue of $0.17 million for the quarter.
Q BioMed(OTCMKTS:QBIO-GET Rating)上一次公佈財報是在7月28日(星期四)。該公司公佈了本季度每股收益(0.06美元)。該公司本季度的收入為17萬美元。
Q BioMed Company Profile
Q BioMed公司簡介
Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.
Q BioMed Inc.是一家生物醫學加速和開發公司,專注於許可、收購和向生命科學和醫療保健公司提供資源。該公司提供氯化鍶SR89和美沙酮,這是一種治療轉移性骨癌疼痛的放射性藥物。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Q BioMed (QBIO)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- 免費獲取有關Q BioMed(QBIO)的StockNews.com研究報告
- 股市:紅海中的三座強國
- 第四季度值得考慮的3家銀行
- 有什麼辦法可以治癒Teladoc股票的問題嗎?
- MarketBeat:回顧一週9/12-9/16
- 沒有人告訴這三隻股票這是下跌的一週
Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
接受Q BioMed Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Q BioMed和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧